Exam Master MA MPJE Review Test Accurate Correct 100%

Interchangeable multi-source drugs - ANSWER -Check Orange Book if "A" rating for same drug product, dosage form, strength -Same drug product, dosage form, strength assigned "A" rating in Orange Book and not listed on Exception List in MLID -If drug is not in Orange Book, it may still be interchangeable if same product, dosage form, strength listed in Additional List of MLID -Practitioner can instruct pharmacist to dispense only brand by writing "no substitution" on Rx Child-resistant packaging - ANSWER Consumer Product Safety Commission (CPSC) -> Poison Prevention Packaging Act -Drugs dispensed to hospital & nursing home patients do not require child-resistant packaging -Drugs intended to be consumed at home require child-resistant packaging -Glass prescription container may be reused if dispensed with new child-resistant cap -Drugs for topical application do not require child-resistant packaging -Patient doesn't have to make request for non-child-resistant containers in writing (but it is strongly encouraged) Authority to place a drug into a controlled substance schedule or to change a schedule - ANSWER Attorney General Pharmacist License Renewal - ANSWER -Applicant for license renewal whose personal registration has been revoked/suspended for 6 months-2 years must take & pass MPJE -Applicant for license renewal whose personal registration has been revoked/suspended > 2 years must take & pass MPJE and may be required to take & pass NAPLEX as well -All pharmacist registrations expire on 12/31 of each EVEN-numbered year Pedigree-related requirements in drug distribution cycle - ANSWER -Pedigree: statement of origin that identifies each prior sale, purchase, or trade of a drug, including dates of transactions, and names and addresses of all parties to them -Wholesalers & repackagers must pass transaction data for any drugs sold to subsequent purchasers -Drug Supply Chain Security Act will require pharmacist to electronically track all products by 2023 -Pharmacist must have systems to quarantine, investigate, and notify FDA of suspect drug products Required patient package inserts for estrogen-containing drug products - ANSWER -Does not apply to progesterone-containing products -If dispensed in acute-care hospitals or LTCF, required patient PIs must be provided to the patients before administration of 1st dose and every 30 days thereafter, as long as therapy continues